Stockhub

XTL Biopharmaceuticals Ltd.: Revision history

View logs for this page

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

21 August 2022

14 August 2022

31 July 2022

  • curprev 21:0321:03, 31 July 2022‎ Chris talk contribs‎ 701 bytes +701‎ Created page with "XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indication..." Tag: Visual edit
Retrieved from ‘https://stockhub.co/research/XTL_Biopharmaceuticals_Ltd.’